Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of BRL-101 in Transfusion-Dependent β-Thalassemia
NCT05577312Phase 2Active, not recruiting
- Sponsor
- BRL Medicine Inc.
- Start
- Nov 2022
- Primary completion
- Oct 2026
- Modality
- Gene Silencing, CRISPR-Cas9, Hematopoietic Stem Cells
- Countries
- 1
01
Overview
A Phase 2 trial of BRL-101 in beta thalassemia, sponsored by BRL Medicine Inc.. Started Nov 2022; status: active, not recruiting.
02
Drugs
BRL-101
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on NCT05577312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05577312.